Meeting
2020 ASCO Virtual Scientific Program
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Authors
Daniel da Motta Girardi
National Cancer Institute, National Institutes of Health, Bethesda, MD
Daniel da Motta Girardi , Scot Anthony Niglio , Amir Mortazavi , Primo Lara Jr., Sumanta K. Pal , Biren Saraiya , Lisa M. Cordes , Lisa Ley , Olena Sierra Ortiz , Jacqueline Cadena , Carlos Diaz , Mohammadhadi H. Bagheri , Seth M. Steinberg , Rene Costello , Howard Streicher , John Wright , Howard L. Parnes , Yang-Min Ning , Donald P. Bottaro , Andrea B. Apolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02496208
Citation
J Clin Oncol 38: 2020 (suppl; abstr 5037)
DOI
10.1200/JCO.2020.38.15_suppl.5037
Abstract #
5037
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase I trial to evaluate the biologic effect of CBM588 (Clostridium butyricum) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC).
First Author: Luis A Meza
Poster
2020 ASCO Virtual Scientific Program
Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).
First Author: Scot Anthony Niglio
Poster
2018 ASCO Annual Meeting
Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naïve (n) or refractory (r) to checkpoint inhibitor (CPI).
First Author: Rosa Nadal
Poster
2017 Genitourinary Cancers Symposium
A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
First Author: Andrea B. Apolo